1887

Abstract

We investigated the protective efficacy of a systemic triple vector (DNA/rSFV/rMVA)-based vaccine against mucosal challenge with pathogenic simian immunodeficiency virus (SIV) in cynomolgus monkeys. Animals were immunized at week 0 with DNA (intradermally), at weeks 8 and 16 with recombinant Semliki Forest virus (rSFV, subcutaneously) and finally, at week 24, with recombinant modified vaccinia virus Ankara strain (rMVA, intramuscularly). Both DNA and recombinant viral vectors expressed a wide range of SIV proteins (Gag, Pol, Tat, Rev, Env and Nef). This immunization strategy elicited cell-mediated rather than humoral responses that were especially increased following the last boost. Upon intrarectal challenge with pathogenic SIVmac251, three of the four vaccinated monkeys dramatically abrogated virus load to undetectable levels up to 41 weeks after challenge. A major contribution to this vaccine effect appeared to be the T-cell-mediated immune response to vaccine antigens (Gag, Rev, Tat, Nef) seen in the early phase of infection in three of the four vaccinated monkeys. Indeed, the frequency of T-cells producing antigen-induced IFN- mirrored virus clearance in the vaccinated and protected monkeys. These results, reminiscent of the efficacy of live attenuated virus vaccines, suggest that vaccination with a combination of many viral antigens can induce a robust and stable vaccine-induced immunity able to abrogate virus replication.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.79794-0
2004-05-01
2019-11-12
Loading full text...

Full text loading...

/deliver/fulltext/jgv/85/5/vir851191.html?itemId=/content/journal/jgv/10.1099/vir.0.79794-0&mimeType=html&fmt=ahah

References

  1. Almond, N., Kent, K., Cranage, M., Rud, E. W., Clarke, B. & Stott, E. J. ( 1995; ). Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 345, 1342–1344.[CrossRef]
    [Google Scholar]
  2. Amara, R. R., Villinger, F., Altman, J. D. & 19 other authors ( 2001; ). Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69–74.[CrossRef]
    [Google Scholar]
  3. Baba, T. W., Liska, V., Khimani, A. H. & 8 other authors ( 1999; ). Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 5, 194–203.[CrossRef]
    [Google Scholar]
  4. Baig, J., Levy, D. B., McKay, P. F. & 19 other authors ( 2002; ). Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination. J Virol 76, 11484–11490.[CrossRef]
    [Google Scholar]
  5. Barouch, D. H., Santra, S., Kuroda, M. J. & 13 other authors ( 2001; ). Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol 75, 5151–5158.[CrossRef]
    [Google Scholar]
  6. Barouch, D. H., Kunstman, J., Kuroda, M. J. & 11 other authors ( 2002; ). Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415, 335–339.[CrossRef]
    [Google Scholar]
  7. Colmenero, P., Berglund, P., Kambayashi, T., Biberfeld, P., Liljeström, P. & Jondal, M. ( 2001; ). Recombinant Semliki Forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response. Gene Ther 8, 1307–1314.[CrossRef]
    [Google Scholar]
  8. Cranage, M. P., Whatmore, A. M., Sharpe, S. A. & 7 other authors ( 1997; ). Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 229, 143–154.[CrossRef]
    [Google Scholar]
  9. Heeney, J. L., Holterman, L., ten Haaft, P., Dubbes, R., Koornstra, W., Teeuwsen, V., Bourquin, P., Norley, S. & Niphuis, H. ( 1994; ). Vaccine protection and reduced virus load from heterologous macaque-propagated SIV challenge. AIDS Res Hum Retrovir 10, S117–S121.
    [Google Scholar]
  10. Heeney, J. L., Koopman, G., Rosenwirth, B. & 12 other authors ( 2000; ). A vaccine strategy utilising a combination of three different chimeric vectors which share specific vaccine antigens. J Med Primatol 29, 268–273.
    [Google Scholar]
  11. Hel, Z., Tryniszewska, E., Tsai, W. P. & 10 other authors ( 2002a; ). Design and in vivo immunogenicity of a polyvalent vaccine based on SIVmac regulatory genes. DNA Cell Biol 21, 619–626.[CrossRef]
    [Google Scholar]
  12. Hel, Z., Nacsa, J., Tryniszewska, E. & 7 other authors ( 2002b; ). Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. J Immunol 169, 4778–4787.[CrossRef]
    [Google Scholar]
  13. Horton, H., Vogel, T. U., Carter, D. K. & 15 other authors ( 2002; ). Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J Virol 76, 7187–7202.[CrossRef]
    [Google Scholar]
  14. Jin, X., Bauer, D. E., Tuttleton, S. E. & 11 other authors ( 1999; ). Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189, 991–998.[CrossRef]
    [Google Scholar]
  15. Johnson, R. P. ( 1996; ). Macaque models for AIDS vaccine development. Curr Opin Immunol 8, 554–560.[CrossRef]
    [Google Scholar]
  16. Johnson, W. E., Lifson, J. D., Lang, S. M., Johnson, R. P. & Desrosiers, R. C. ( 2003; ). Importance of B-cell responses for immunological control of variant strains of simian immunodeficiency virus. J Virol 77, 375–381.[CrossRef]
    [Google Scholar]
  17. Klavinskis, L. S., Bergmeier, L. A., Gao, L., Mitchell, E., Ward, R. G., Layton, G., Brookes, R., Meyers, N. J. & Lehner, T. ( 1996; ). Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes. J Immunol 157, 2521–2527.
    [Google Scholar]
  18. Lehner, T., Wang, Y., Ping, L. & 8 other authors ( 1999; ). The effect of route of immunization on mucosal immunity and protection. J Infect Dis 179, S489–S492.[CrossRef]
    [Google Scholar]
  19. Makitalo, B., Bottiger, P., Biberfeld, G. & Thorstensson, R. ( 2000; ). Cell-mediated immunity to low doses of SIVsm in cynomolgus macaques did not confer protection against mucosal rechallenge. Vaccine 19, 298–307.[CrossRef]
    [Google Scholar]
  20. McChesney, M. B., Collins, J. R., Lu, D., Lu, X., Torten, J., Ashley, R. L., Cloyd, M. W. & Miller, C. J. ( 1998; ). Occult systemic infection and persistent simian immunodeficiency virus (SIV)-specific CD4+-T-cell proliferative responses in rhesus macaques that were transiently viremic after intravaginal inoculation of SIV. J Virol 72, 10029–10035.
    [Google Scholar]
  21. Mitchell, E. A., Bergmeier, L. A., Doyle, C., Brookes, R., Hussain, L. A., Wang, Y. & Lehner, T. ( 1998; ). Homing of mononuclear cells from iliac lymph nodes to the genital and rectal mucosa in non-human primates. Eur J Immunol 28, 3066–3074.[CrossRef]
    [Google Scholar]
  22. Mooij, P. & Heeney, J. L. ( 2001; ). Rational development of prophylactic HIV vaccines based on structural and regulatory proteins. Vaccine 20, 304–321.[CrossRef]
    [Google Scholar]
  23. Negri, D. R., Baroncelli, S., Michelini, Z. & 12 other authors ( 2001; ). Effect of vaccination with recombinant modified vaccinia virus Ankara expressing structural and regulatory genes of SIVmacJ5 on the kinetics of SIV replication in cynomolgus monkeys. J Med Primatol 30, 197–206.[CrossRef]
    [Google Scholar]
  24. Nilsson, C., Sutter, G., Walther-Jallow, L. & 7 other authors ( 2002; ). Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques. J Gen Virol 83, 807–818.
    [Google Scholar]
  25. Norley, S., Beer, B., Binninger-Schinzel, D., Cosma, C. & Kurth, R. ( 1996; ). Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus. Virology 219, 195–205.[CrossRef]
    [Google Scholar]
  26. Osterhaus, A. D. M. E., van Baalen, C. A., Gruters, R. A. & 9 other authors ( 1999; ). Vaccination with Rev and Tat against AIDS. Vaccine 17, 2713–2714.[CrossRef]
    [Google Scholar]
  27. Pal, R., Venzon, D., Letvin, N. L. & 17 other authors ( 2002; ). ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol 76, 292–302.[CrossRef]
    [Google Scholar]
  28. Peng, B., Voltan, R., Lim, L. & 10 other authors ( 2002; ). Rhesus macaque resistance to mucosal simian immunodeficiency virus infection is associated with a postentry block in viral replication. J Virol 76, 6016–6026.[CrossRef]
    [Google Scholar]
  29. Rasmussen, R. A., Hofmann-Lehmann, R., Li, P. L. & 8 other authors ( 2002; ). Neutralizing antibodies as a potential secondary protective mechanism during chronic SHIV infection in CD8+ T-cell-depleted macaques. AIDS 16, 829–838.[CrossRef]
    [Google Scholar]
  30. Robinson, H. L. ( 2002; ). New hope for an AIDS vaccine. Nat Rev Immunol 2, 239–250.[CrossRef]
    [Google Scholar]
  31. Robinson, H. L., Montefiori, D. C., Johnson, R. P. & 14 other authors (1999; ). Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 5, 526–534.[CrossRef]
    [Google Scholar]
  32. Rossio, J. L., Esser, M. T., Suryanarayana, K. & 10 other authors ( 1998; ). Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol 72, 7992–8001.
    [Google Scholar]
  33. Rud, E. W., Cranage, M., Yon, J., Quirk, J., Ogilvie, L., Cook, N., Webster, S., Dennis, M. & Clarke, B. E. ( 1994; ). Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants. J Gen Virol 75, 529–543.[CrossRef]
    [Google Scholar]
  34. Schmitz, J. E., Kuroda, M. J., Santra, S. & 13 other authors ( 1999; ). Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283, 857–860.[CrossRef]
    [Google Scholar]
  35. Sernicola, L., Corrias, F., Koanga-Mogtomo, M. L. & 10 other authors ( 1999; ). Long-lasting protection by live attenuated simian immunodeficiency virus in cynomolgus monkeys: no detection of reactivation after stimulation with a recall antigen. Virology 256, 291–302.[CrossRef]
    [Google Scholar]
  36. Shiver, J. W., Fu, T. M., Chen, L. & 49 other authors ( 2002; ). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331–335.[CrossRef]
    [Google Scholar]
  37. Stevceva, L., Alvarez, X., Lackner, A. A., Tryniszewska, E., Kelsall, B., Nacsa, J., Tartaglia, J., Strober, W. & Franchini, G. ( 2002; ). Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIVgpe recombinant vaccine result in Gag-specific CD8+ T-cell responses in mucosal tissues of macaques. J Virol 76, 11659–11676.[CrossRef]
    [Google Scholar]
  38. Stott, J. & Almond, N. ( 1995; ). Assessing animal models of AIDS. Nat Med 1, 295–297.[CrossRef]
    [Google Scholar]
  39. ten Haaft, P., Verstrepen, B., Uberla, K., Rosenwirth, B. & Heeney, J. L. ( 1998; ). A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. J Virol 72, 10281–10285.
    [Google Scholar]
  40. ten Haaft, P., Almond, N., Biberfeld, G. & 9 other authors ( 2001; ). Comparison of early plasma RNA loads in different macaque species and the impact of different routes of exposure on SIV/SHIV infection. J Med Primatol 30, 207–214.[CrossRef]
    [Google Scholar]
  41. Titti, F., Sernicola, L., Geraci, A. & 12 other authors ( 1997; ). Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys. J Gen Virol 78, 2529–2539.
    [Google Scholar]
  42. Trivedi, P., Horejsh, D., Hinds, S. B., Hinds, P. W., II, Wu, M. S., Salvato, M. S. & Pauza, C. D. ( 1996; ). Intrarectal transmission of simian immunodeficiency virus in rhesus macaques: selective amplification and host responses to transient or persistent viremia. J Virol 70, 6876–6883.
    [Google Scholar]
  43. Tubulekas, I., Berglund, P., Fleeton, M. & Liljeström, P. ( 1997; ). Alphavirus expression vectors and their use as recombinant vaccines: a minireview. Gene 190, 191–195.[CrossRef]
    [Google Scholar]
  44. Warren, J. ( 2002; ). Preclinical AIDS vaccine research: survey of SIV, SHIV, and HIV challenge studies in vaccinated nonhuman primates. J Med Primatol 31, 237–256.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.79794-0
Loading
/content/journal/jgv/10.1099/vir.0.79794-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error